Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00125567
Status:
COMPLETED
Last Update Posted:
2009-06-22
First Post:
2005-07-29
Brief Title:
Stalevo in Early Wearing-Off Patients
Sponsor:
Orion Corporation Orion Pharma
Organization:
Orion Corporation Orion Pharma
Study Overview
Official Title:
Multicentre Randomised Double-Blind Study to Compare Stalevo to LevodopaCarbidopa in Patients With Parkinsons Disease Experiencing Symptoms of Early Wearing-Off
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SEWOP
Brief Summary:
The purpose of this study is to demonstrate in patients with Parkinsons disease that when compared to levodopacarbidopa Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian medication is required due to inadequately controlled parkinsonian symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT number 2004-005234-39 | None | None | None |